The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Systematic review comparing allogeneic transplant patients with non-transplant patients in MF
Jan Philipp Bewersdorf, MD, Yale School of Medicine, New Haven, CT, discusses the findings of a systematic review evaluating the effect of allogeneic transplant in patients with myelofibrosis (MF). Currently, the only disease-modifying treatment for MF is allogeneic transplant. However, high rate of graft failure and poor performance status of older patients are obstacles to this treatment. Dr Bewersdorf outlines the findings of this investigation and highlights a long-term survival benefit observed in MF patients who opt for transplant over non-transplant patients who are instead treated with JAK inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
